Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBITDA Margin (2016 - 2026)

Ocular Therapeutix has reported EBITDA Margin over the past 13 years, most recently at 865.46% for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 26799.0% year-over-year to 865.46%; the TTM value through Mar 2026 reached 575.42%, down 23327.0%, while the annual FY2025 figure was 519.75%, 25018.0% down from the prior year.
  • EBITDA Margin for Q1 2026 was 865.46% at Ocular Therapeutix, down from 526.49% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 127.41% in Q3 2023 and troughed at 865.46% in Q1 2026.
  • A 5-year average of 307.05% and a median of 214.0% in 2024 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 14028bps in 2022 and later crashed -38346bps in 2025.
  • Year by year, EBITDA Margin stood at 137.56% in 2022, then rose by 2bps to 135.46% in 2023, then tumbled by -119bps to 296.08% in 2024, then crashed by -78bps to 526.49% in 2025, then tumbled by -64bps to 865.46% in 2026.
  • Business Quant data shows EBITDA Margin for OCUL at 865.46% in Q1 2026, 526.49% in Q4 2025, and 472.35% in Q3 2025.